Ono K, Ono H, Toi Y, et al. - Researchers examined the relationship between checkpoint inhibitor pneumonitis (CIP) and the clinical efficacy of anti-programmed cell death-1 antibody in patients suffering from advanced non-small cell lung cancer (NSCLC). This study included 203 advanced NSCLC patients who were treated with nivolumab or pembrolizumab between January 2016 and August 2019. Patients with and without CIP were compared. Findings revealed prolonged progression-free survival as well as overall survival in relation to CIP. No tumor growth occurred for long periods post-treatment cessation in 25% of CIP patients. The best clinical efficacy of anti-programmed cell death-1 antibody can be achieved by careful management of CIP.